What is GLORY-1?
GLORY-1 is an innovative investigational therapy in the field of metabolic health, designed as a dual receptor agonist targeting both…
GLORY-1 is an innovative investigational therapy in the field of metabolic health, designed as a dual receptor agonist targeting both…
A landmark Phase 3 clinical study of mazdutide, the world’s first dual glucagon (GCG)/glucagon-like peptide-1 (GLP-1) receptor agonist, has been…
The global obesity drug market is experiencing significant growth, with projections exceeding $150 billion annually in the coming decade. This…
Key Findings at a Glance The Study: How Weight-Loss Drugs Stack Up Against Surgery A landmark Israeli study (presented at the European Congress…
New SURMOUNT-5 Trial Results (2025) Key Takeaways ✅ Tirzepatide (Zepbound) led to significantly greater weight loss than semaglutide (Wegovy). Background: The…
Obesity doesn’t happen overnight—it creeps in due to metabolic, hormonal, and lifestyle changes that start in your 20s. Catching early warning signs…
A Scientific Mystery Solved In a breakthrough that defies conventional logic, researchers have discovered that two completely opposite drug strategies—stimulating and blocking the same…